GUJRATHI SHEILA — SEC Form 4 filings
SEC reporting owner CIK 1575202. 10 Form 4 filings on record with FilingPulse; latest filed 2026-07-30.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-01-23 to 2026-07-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 130,000 shares, $300,573 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 19.
- Largest priced transaction: purchase of 130,000 shares @ $2.31 ($300,573) in Ventyx Biosciences, Inc., filed 2024-12-26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Ventyx Biosciences, Inc. (VTYX) | Director | 5 | 1 leg · 130,000 sh · $300,573 | — | 11 |
| Janux Therapeutics, Inc. (JANX) | Director | 4 | — | — | 6 |
| Processa Pharmaceuticals, Inc. (PCSA) | Director | 1 | — | — | 2 |
Form 4 filings — GUJRATHI SHEILA
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-30 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Grant/award (A): 70,811.88 (derivative) · Grant/award (A): 12,311.28 (derivative) | EDGAR |
| 2026-03-04 | 4 | Ventyx Biosciences, Inc. (VTYX) | Disposition to issuer (D): 130,000 · Disposition to issuer (D): 33,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 662,369 (derivative) · Disposition to issuer (D): 277,941 (derivative) · +2 more | EDGAR |
| 2025-06-13 | 4 | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Ventyx Biosciences, Inc. (VTYX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-12-26 | 4 | Ventyx Biosciences, Inc. (VTYX) | Purchase (P): 130,000 @ $2.31 | EDGAR |
| 2024-11-07 | 4 | Janux Therapeutics, Inc. (JANX) | Other (J): 4,611 @ $0 | EDGAR |
| 2024-06-28 | 4 | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 2,500 @ $0 · Grant/award (A): 8,350 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Ventyx Biosciences, Inc. (VTYX) | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Janux Therapeutics, Inc. (JANX) | Other (J): 2,986 @ $0 | EDGAR |
| 2024-01-23 | 4 | Ventyx Biosciences, Inc. (VTYX) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1575202 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →